What question did this study set out to answer?

This review aims to assess the clinical applicability of therapeutic drug monitoring and model-informed precision dosing for oral targeted agents.

June 14, 2026Clinical PharmacokineticsOpen Access

Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation

View Full Paper

Ask AI

Bookmark

Authors

ARArnau Torrent RodríguezHospital Clínic de Barcelona CBCarla BastidaHospital Clínic de Barcelona EMEsther Carcelero San MartínHospital Clínic de Barcelona

Discussion

Member takes

Implication

Randomized trial evaluates therapeutic drug monitoring and precision dosing in oncology, suggesting refined strategies for individualized patient care.

Key Points

This review aims to assess the clinical applicability of therapeutic drug monitoring and model-informed precision dosing for oral targeted agents.
Evaluated interindividual pharmacokinetic variability in solid tumors and hematologic malignancies.
Assessed exposure-response relationships, validated assays, and actionable concentration thresholds for selected agents.
Integrated therapeutic drug monitoring usefulness score and reviewed high-level evidence from prospective interventional studies.
Imatinib and sunitinib showed improved outcomes with defined trough concentration targets (p<0.05).
Alectinib, cabozantinib, and lenvatinib support selective implementation due to consistent exposure-response relationships.
Monitoring of osimertinib and olaparib is most relevant in toxicity-driven scenarios, while lorlatinib lacks a defined therapeutic window.

Cite This Study

Rodríguez et al. (2026) studied this question.

synapsesocial.com/papers/6a2e4753b1cc60ccdea8bd40 https://doi.org/10.1007/s40262-026-01660-2

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates therapeutic drug monitoring and precision dosing in oncology, suggesting refined strategies for individualized patient care.

Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation

Discussion

Member takes

Implication

Key Points

Cite This Study

Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider